Clorox (NYSE:CLX) Price Target Raised to $114.00 at Deutsche Bank Aktiengesellschaft

Clorox (NYSE:CLX) had its price target upped by Deutsche Bank Aktiengesellschaft from $110.00 to $114.00 in a research note released on Friday, MarketBeat.com reports. Deutsche Bank Aktiengesellschaft currently has a hold rating on the stock.

Several other equities analysts have also weighed in on the stock. Rothschild & Co Redburn reduced their target price on shares of Clorox from $120.00 to $115.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Clorox in a research report on Friday, January 9th. Wells Fargo & Company raised their target price on Clorox from $108.00 to $115.00 and gave the company an “equal weight” rating in a report on Friday. Barclays restated an “underweight” rating and issued a $109.00 price target on shares of Clorox in a report on Friday, January 16th. Finally, UBS Group dropped their price objective on shares of Clorox from $119.00 to $115.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 14th. One equities research analyst has rated the stock with a Buy rating, thirteen have issued a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat.com, Clorox presently has a consensus rating of “Reduce” and a consensus price target of $122.19.

Clorox Trading Up 1.1%

Shares of CLX opened at $113.46 on Friday. The company has a current ratio of 0.76, a quick ratio of 0.50 and a debt-to-equity ratio of 18.01. The firm has a market capitalization of $13.84 billion, a P/E ratio of 17.81, a price-to-earnings-growth ratio of 0.56 and a beta of 0.58. The stock’s fifty day simple moving average is $103.80 and its 200 day simple moving average is $114.86. Clorox has a twelve month low of $96.66 and a twelve month high of $164.22.

Clorox (NYSE:CLX) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.07. The company had revenue of $1.43 billion for the quarter, compared to the consensus estimate of $1.41 billion. Clorox had a return on equity of 358.39% and a net margin of 11.68%.The company’s quarterly revenue was down 18.9% compared to the same quarter last year. During the same period last year, the business posted $1.86 EPS. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. On average, equities research analysts forecast that Clorox will post 7.15 earnings per share for the current year.

Clorox Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Wednesday, January 28th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date is Wednesday, January 28th. Clorox’s dividend payout ratio is 77.86%.

Insider Buying and Selling at Clorox

In related news, Director Pierre R. Breber bought 4,000 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was bought at an average price of $104.13 per share, with a total value of $416,520.00. Following the transaction, the director owned 13,000 shares of the company’s stock, valued at approximately $1,353,690. This trade represents a 44.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.63% of the company’s stock.

Institutional Trading of Clorox

Hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. lifted its holdings in Clorox by 138.3% during the 2nd quarter. Invesco Ltd. now owns 3,245,175 shares of the company’s stock worth $389,648,000 after buying an additional 1,883,465 shares during the last quarter. Norges Bank acquired a new stake in shares of Clorox during the 2nd quarter valued at approximately $190,429,000. Van ECK Associates Corp lifted its stake in Clorox by 93.9% during the third quarter. Van ECK Associates Corp now owns 2,709,972 shares of the company’s stock worth $334,139,000 after purchasing an additional 1,312,471 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Clorox by 218.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,249,127 shares of the company’s stock worth $149,983,000 after purchasing an additional 856,873 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC bought a new stake in Clorox during the second quarter valued at $71,856,000. 78.53% of the stock is owned by institutional investors.

Key Headlines Impacting Clorox

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Clorox agreed to acquire GOJO Industries, the maker of Purell, for $2.25 billion in cash — a strategic push deeper into skin health and hygiene that management says is growth‑accretive and advances its IGNITE plan. The deal expands Clorox’s consumer and professional hygiene footprint and is the primary catalyst for today’s stock strength. Clorox Announces Acquisition of GOJO
• Positive Sentiment: Management updated FY‑2026 EPS guidance to $5.95–$6.30, slightly above consensus, and reiterated revenue targets — a sign the company expects the combined portfolio and cost initiatives to help stabilize growth. This guidance helped reassure investors even as organic revenue pressures persist. (Company guidance release)
• Neutral Sentiment: Deutsche Bank raised its price target on CLX to $114 (keeps a Hold rating), a small incremental positive that signals modest upside in analysts’ view but not a strong buy signal. Deutsche Bank Raises Price Target
• Neutral Sentiment: Broad media and analyst coverage (WSJ, CNBC, MarketWatch) has amplified the deal’s reach and provided investors with deal details and management commentary — increasing attention but not resolving long‑term execution questions. WSJ: Clorox to Buy Purell-Maker
• Negative Sentiment: Some sell‑side skepticism remains: Barclays kept an Underweight (sell) stance despite a small target tweak, and commentary from critics highlights valuation and fundamental concerns that could limit upside until integration is proven. Barclays Remains a Sell
• Negative Sentiment: The deal is being financed with debt, increasing leverage and short‑term balance‑sheet risk; investors will watch integration execution and cost synergy realization closely — these risks are why some analysts remain cautious. WSJ: Deal Financed with Debt
• Negative Sentiment: Critical commentary (e.g., Seeking Alpha) questions whether the acquisition meaningfully fixes Clorox’s underlying growth challenges and suggests the company still needs stronger organic execution — a narrative that could cap the stock if results don’t improve. Seeking Alpha: Adding Sanitizers, But In Need Of Getting Its Hands Dirty

Clorox Company Profile

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.